Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

William Grainger

Neurology Gilbert, AZ Medical Doctor

NPI 1003963679 CMS profile 990223

726 N Greenfield Rd, Suite 110, Gilbert, AZ 85234

Open in the dashboard

General payments

$211,399

810 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$126,972 paid to institutions, not to them · program years 2019–2022

Through program year 2023, William Grainger of Gilbert, AZ is reported in the CMS Open Payments database as having received $211,399 across 810 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $126,972 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $13,101 21
2022 General $24,276 120
2021 General $66,019 215
2020 General $26,785 171
2019 General $81,218 283

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Grainger
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to William Grainger were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year William Grainger Neurology median Middle half National median
2019 $81,218 $474 $118–$2,177 $163
2020 $26,785 $367 $82–$2,309 $114
2021 $66,019 $438 $104–$2,547 $132
2022 $24,276 $442 $103–$2,388 $149
2023 $13,101 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Biogen, Inc. $154,893 272 payments
  2. Genentech USA, Inc. $17,641 34 payments
  3. Amgen Inc. $16,193 67 payments
  4. Teva Pharmaceuticals USA, Inc. $14,449 38 payments
  5. Celgene Corporation $1,505 15 payments
  6. Novartis Pharmaceuticals Corporation $901 34 payments
  7. Allergan Inc. $597 34 payments
  8. EMD Serono, Inc. $561 20 payments
  9. AbbVie, Inc. $503 38 payments
  10. Alexion Pharmaceuticals, Inc. $391 14 payments
  11. Other $3,764 244 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $148,794 77 payments
  2. Consulting Fee $24,921 12 payments
  3. Travel and Lodging $20,881 94 payments
  4. Food and Beverage $16,713 617 payments
  5. Education $89 10 payments
Products named General payments · program years 2019–2023
  1. TYSABRI $69,581 100 payments
  2. VUMERITY $60,528 108 payments
  3. TECFIDERA $22,719 38 payments
  4. OCREVUS $17,587 32 payments
  5. AIMOVIG $16,492 84 payments
  6. Ajovy Central Nervous System $11,509 25 payments
  7. AJOVY Central Nervous System $2,918 12 payments
  8. AVONEX $2,092 18 payments
  9. PLEGRIDY $2,048 3 payments
  10. Ozanimod $1,288 9 payments
  11. Other $6,801 393 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

810 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record